Stage III oral cavity cancer is characterized by larger tumors or lymph node involvement, often diagnosed through physical ...
AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...
A new case report published in Annals of Internal Medicine describes a novel approach for treating fibrosing mediastinitis ...
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has developed and validated an artificial intelligence (AI)–based noninvasive tool that can predict the likelihood ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, ...
Is omission of the sentinel lymph node biopsy safe in early breast cancer in patients treated with breast conserving therapy ...
SAN ANTONIO -- Many patients with early breast cancer can safely skip sentinel lymph node biopsy (SLNB), results of a large ...
Less-invasive lymph node procedures are noninferior to axillary lymph node dissection for 3-year recurrence outcomes in breast cancer patients.
As I was getting up from my visit with Mrs. Gregory, her right hand went to the base of her neck. Dr. Smith, do you think ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, ...
The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the ...